Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04009499 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
A Phase 3 study of Psoriatic Arthritis, sponsored by UCB Biopharma SRL.
- Active
- Registry status
- Phase 3
- Development phase
- 1,131
- Enrollment target
- 20
- Study locations
NCT04009499 is a Phase 3 study of Psoriatic Arthritis that is active but no longer recruiting, run by UCB Biopharma SRL. The registered enrollment target is 1,131 participants, above the 829-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (36% higher). The trial reports 20 study locations across 16 states.
The verdict
NCT04009499, a Phase 3 study of Psoriatic Arthritis, is active but no longer recruiting, sponsored by UCB Biopharma SRL.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,131 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study to assess the long-term safety, long-term efficacy and tolerability of bimekizumab administered subcutaneously (sc) in adult subjects with psoriatic arthritis (PsA).
Conditions Studied
Interventions
- DRUG Bimekizumab
Study Locations (20)
New York
- Pa0012 50010 - Brooklyn
- Pa0012 50011 - New York
- Pa0012 50034 - Rochester
Florida
- Pa0012 50033 - Palm Harbor
- Pa0012 50037 - Tampa
North Carolina
- Pa0012 50125 - Charlotte
- Pa0012 50031 - Salisbury
Arizona
- Pa0012 50017 - Phoenix
California
- Pa0012 50035 - San Diego
Georgia
- Pa0012 50039 - Atlanta
Idaho
- Pa0012 50024 - Boise
Kentucky
- Pa0012 50028 - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,131 participants |
| Start Date | 2019-08-13 |
| Est. Completion | 2026-05-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04009499
The ClinicalTrials.gov registry entry for NCT04009499 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,131 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 829-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (36% higher). The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Bimekizumab is the first listed.
NCT04009499 reports 20 study locations spanning 16 distinct geographic areas - top geographies include New York, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04009499 about?
NCT04009499 is a clinical study titled "A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis". This is a study to assess the long-term safety, long-term efficacy and tolerability of bimekizumab administered subcutaneously (sc) in adult subjects with psoriatic arthritis (PsA).
What is the current status of trial NCT04009499?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,131 participants. The study started on 2019-08-13. Estimated completion is 2026-05-25.
What conditions does trial NCT04009499 study?
This clinical trial studies the following conditions: Psoriatic Arthritis.
What interventions are being tested in trial NCT04009499?
The interventions under investigation include: Bimekizumab (DRUG).
Who is sponsoring clinical trial NCT04009499?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04009499 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
RECRUITING · Phase 3
-
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
RECRUITING · Phase 3
-
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.